EQS News: Marinomed Biotech AG / Keyword(s): Personnel Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations March 1, 2024 / 07:45 CET/CEST The issuer/publisher is responsible for the content of the announcement. ═════════════════════════════════════════ ═════════ ════════════════════════ Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations Korneuburg, Austria, March 1, 2024 – Lucia Ziegler takes over At the beginning of March 2024, he will head the now integrated “Investor & Public Relations” department at Marinomed Biotech AG (VSE:MARI). In addition to her previous PR tasks, Lucia Ziegler is also responsible for the IR area of the biotechnology company. She will take over the IR agenda from Stephanie Kniep, who will remain associated with Marinomed. Lucia Ziegler holds a Master of Science in Molecular Biology from the University of Vienna and has successfully built up the public relations and social media department at Marinomed over the last three years. “With IR and PR activities under one management, we bring together what belongs together. We create the conditions to make our stakeholder communication even better and more efficient. Lucia Ziegler has already set important accents in the perception of Marinomed by redesigning the website and further developing the annual report. In her expanded area of responsibility, she will continue to sharpen the presentation of Marinomed’s positioning, strategy and future potential to shareholders, investors, business partners and the media. “I would like to thank Stephanie Kniep for her commitment and the valuable development of our IR activities on the international capital markets,” said Andreas Grassauer, CEO of Marinomed. About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotechnology company with a growing development pipeline and globally marketed therapeutics. The company develops patent-protected, innovative products in the therapeutic areas of immunology and virology based on its Marinosolv® platform and the virus-blocking effect of Carragelose®. The Marinosolv® technology increases the solubility and bioavailability of poorly soluble active ingredients and is used to develop new therapeutics for indications in the area of autoreactive immune diseases. The Virology segment includes Carragelose®-based over-the-counter products for the prophylaxis and treatment of viral upper respiratory tract infections, partnered in more than 40 countries. The company is based in Korneuburg, Austria and is listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information: (1) https://www.marinomed.com.
Inquiry note: Marinomed Biotech AG International media inquiries IR & PR: Lucia Ziegler Metrum Communications: Roland Mayrl T: +43 2262 90300 158 T: +43 664 6126228 E-mail: (2)ir@marinomed.com E-Mail: (4)marinomed@metrum.at E-Mail: (3)pr@marinomed.com ═══════════════════════════════════════ ════════ ═══════════════════════════ 03/01/2024 CET/CEST Publication of a corporate news/financial announcement, transmitted by EQS Group AG. www.eqs.com
═════════════════════════════════════════ ═════════ ════════════════════════ Language: German Company: Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria Telephone: +43 2262 90300 Email: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6 WKN: A2N9MM Stock exchanges: open market in Berlin, Düsseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (official trading) EQS News ID: 1848777 End of the announcement EQS News Service 1848777 03/01/2024 CET/CEST References Visible links 1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=1848777&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. and@marinomed.com
3. pr@marinomed.com
4. marinomed@metrum.at